Drug Trial Radar · NCT03199872
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Mar 30, 2017
Primary completion
Aug 1, 2018
Study completion Mar 29, 2019
Sponsor
- Lead sponsor
- RhoVac APSIndustry
- Sponsor type
- Industry
- Collaborators
- Dantrials Aps
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer
Conditions
- Prostate Cancer
Interventions
RV001VBiological
Sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportions of Participants With Treatment-related Adverse EventsTime frame: 8 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.